Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
about
Review and management of drug interactions with boceprevir and telaprevirWater, electrolytes, and acid-base alterations in human immunodeficiency virus infected patientsPre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challengesManagement of patients with hepatitis B who require immunosuppressive therapyThe role of drug transporters in the kidney: lessons from tenofovirTenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patientsOral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesHIV and kidney diseases: 35 years of history and consequencesAntiretroviral prophylaxis for HIV prevention in heterosexual men and womenCost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringRole of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012Screening for decreased glomerular filtration rate and associated risk factors in a cohort of HIV-infected patients in a middle-income countryA randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individualsRisk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentComparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trialCharacteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 preventionKidney Disease and HIV Infection.Association of tenofovir disoproxil fumarate with primary allograft survival in HIV-positive kidney transplant recipients.Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Correlates of Awareness of and Willingness to Use Pre-exposure Prophylaxis (PrEP) in Gay, Bisexual, and Other Men Who Have Sex with Men Who Use Geosocial-Networking Smartphone Applications in New York City.Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.Pre-exposure prophylaxis for HIV prevention in women: current perspectivesRisks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho.HIV-exposed infants: rethinking care for a lifelong condition.Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposureRenal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapineThe New Epidemiology of HIV-Related Kidney Disease.Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.AASLD guidelines for treatment of chronic hepatitis B.Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis BClinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial
P2860
Q24628716-E7D70738-2376-4A12-A42F-E14AA6CF7126Q26770753-FA4D9F9A-AFBA-45D0-9D49-4BC7D699FF97Q26825641-F24593A6-A66A-41D9-93D2-70B2BC1E3D11Q26853490-154DFB3D-8E64-4194-A5ED-3DA68057C591Q26866489-5AEF0295-D850-4EDD-825D-2D97F89C1D7CQ26995852-BFB7FF87-42DF-4B28-BEA3-CB24B5A83F17Q27009523-FD44C8E0-B12C-4752-9F6F-69A8165BE8EDQ27023352-1EAD266A-8AE6-4506-9493-1EC10ED8EF64Q28069641-902A5CBB-31F3-446E-AFE8-6252D1C65FD0Q28270788-A246E480-AA02-4A73-ADBB-70DC4DD97F64Q28482138-0D004E6B-E077-4E1A-B03E-1BBD8FAFF428Q28533843-F1E57FCB-8128-4653-9F47-FF5A5969ECBEQ28541930-7DAE130F-C9C7-4704-B878-E05DBE4E3514Q28543212-4CD4C9E6-D9EF-4D98-BBAD-57517B5AAD21Q28554081-F1B07179-A0FA-4817-B2FE-C8405B6A8899Q28730855-462DEFC3-260C-410E-A2C8-E2EC5A2D75AAQ28744206-CC50AA23-2F70-4675-B8DE-DBEC25431DA5Q30234837-BBD81756-CCC8-4C73-9A02-0E2F1A673D86Q30252384-44259A02-7FA4-4B4F-89F6-21D92F658187Q30744184-6A81DC26-E22B-4805-86EE-B83867903AE8Q31028855-E8606036-CFDB-4EC9-A85D-5EAEEF8CE9EEQ33447623-9B19B45D-61FF-4AFE-8A76-72AC9B06F1D1Q33460754-2527AADF-31E1-4E68-9982-BEC165BB0098Q33766562-B70BC40E-5005-4981-B194-684B5E653505Q33841718-0D564CEA-C180-4BC9-B70A-C27286699913Q33847019-0219EB03-209E-45A1-831A-E1DA28557A86Q33871174-8AA7E270-C0F1-45A0-9F5E-A63F45EB322EQ33880241-3670ED51-5120-4031-9208-3C44D84FF0B6Q34126724-2657BD4B-DEBE-4421-9C8B-22F0425FCC4BQ34206774-A6B88B25-A1EC-47C7-B8A9-1FEAA3DC9FC4Q34250879-A9414C0F-EB38-403A-90C3-8A1EF5B15B65Q34307868-9538E204-7EE6-415D-899B-8964AE93037BQ34405008-0B44E248-8BDC-4E6C-A00E-0FC01A3353F5Q34478840-FA9DA7F8-722E-4AEA-8F78-697AF16C7BB5Q34501660-D83069C2-31FE-442D-B449-8597F994829EQ34536677-CAE74E49-C847-4051-8DC6-0DF44D63AAFBQ34579911-10081E0A-EAD4-4D4C-95B8-4DF7A87F5514Q34736194-A75E06F6-FFAD-4DBA-B74E-9662C7A3B674Q34736818-EE78EF03-E5DF-43B3-B923-96425A60378FQ34952127-4AC3FC2D-40C4-43D3-A549-414E272CA710
P2860
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Systematic review and meta-ana ...... rate in HIV-infected patients.
@ast
Systematic review and meta-ana ...... rate in HIV-infected patients.
@en
type
label
Systematic review and meta-ana ...... rate in HIV-infected patients.
@ast
Systematic review and meta-ana ...... rate in HIV-infected patients.
@en
prefLabel
Systematic review and meta-ana ...... rate in HIV-infected patients.
@ast
Systematic review and meta-ana ...... rate in HIV-infected patients.
@en
P2093
P356
P1476
Systematic review and meta-ana ...... rate in HIV-infected patients.
@en
P2093
Nathaniel Smith
Philip Keiser
Ryan D Cooper
Saraladevi Naicker
P304
P356
10.1086/655681
P407
P577
2010-09-01T00:00:00Z